Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 12/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075001 | 1.00 | REN (0.42) | RENDPP4KCNH2FAPPREP | |
| SCHEMBL10074457 | 0.91 | DPP4 (0.41) | RENDPP4KCNH2FAPPREP | |
| SCHEMBL10074326 | 0.91 | DPP4 (0.41) | RENDPP4KCNH2FAPPREP | |
| SCHEMBL10077081 | 0.91 | DPP4 (0.39) | RENDPP4KCNH2FAPPREP | |
| SCHEMBL10078067 | 0.88 | DPP4 (0.41) | RENDPP4DPP9DPP8DPP7 | |
| SCHEMBL10078066 | 0.87 | REN (0.37) | RENDPP4KCNH2FAPDPP9 | |
| SCHEMBL10077057 | 0.85 | REN (0.36) | RENDPP4DPP9DPP8DPP7 | |
| SCHEMBL13194653 | 0.83 | REN (0.41) | RENDPP4KCNH2FAPPREP | |
| SCHEMBL6874726 | 0.83 | REN (0.41) | RENDPP4KCNH2FAPPREP | |
| SCHEMBL10074281 | 0.83 | DPP4 (0.41) | RENDPP4KCNH2FAPPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | REN 449/4885DPP4 121/4885KCNH2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.